Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - estradiol hemihydrate; dydrogesterone - film-coated tablet - 1/10 milligram(s) - progestogens and estrogens, sequential preparations; dydrogesterone and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - estradiol hemihydrate; dydrogesterone - film-coated tablet - 2/10 milligram(s) - progestogens and estrogens, sequential preparations; dydrogesterone and estrogen

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

orifarm - estradiol hemihydrate; dydrogesterone - film-coated tablet - 1 mg - 5 mg - estradiol hemihydrate; dydrogesterone 5 mg - dydrogesterone and estrogen

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - dydrogesterone, quantity: 10 mg; estradiol, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; colloidal anhydrous silica; lactose monohydrate; maize starch; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

orifarm - dydrogesterone; estradiol hemihydrate - film-coated tablet - 0,5 mg - 2,5 mg - dydrogesterone 2.5 mg; estradiol hemihydrate - dydrogesterone and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - estradiol hemihydrate dydrogesterone - film coated tablet - 1/5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

bgp products ltd - estradiol hemihydrate, dydrogesterone - film coated tablet - 1 mg, 10 m milligram - progestogens and estrogens, sequential preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - estradiol hemihydrate dydrogesterone - film coated tablet - 1 mg, 10 m milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

bgp products ltd - estradiol hemihydrate, dydrogesterone - film coated tablet - 2 mg, 10 m milligram - progestogens and estrogens, sequential preparations - sequential hormone replacement therapy - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women at least 6 months since the last menses. prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.